Evidence map›Paper›PMID 27845373›Full record

ArticleScientific reports2016

Novel synthetic (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol inhibits arthritis by targeting signal transducer and activator of transcription 3.

Dong Ju Son, Dae Hwan Kim, Seong-Su Nah, Mi Hee Park, Hee Pom Lee, Sang Bae Han, Udumula Venkatareddy, Benjamin Gann, Kevin Rodriguez, Scott R Burt and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MMPP promotes adipogenesis and glucose uptakeFrontiers in pharmacology · 2022
    Article
  6. Article
  7. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues.International journal of molecular sciences · 2018
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Dong Ju SonCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Dae Hwan KimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Seong-Su NahDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Asan, Chungnam 31538, Korea.
Mi Hee ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Hee Pom LeeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Sang Bae HanCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Udumula VenkatareddyDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84604, USA.
Benjamin GannDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84604, USA.
Kevin RodriguezDepartment of Chemistry, Utah Valley University, 800 W University Pkwy, Orem, UT 84058, USA.
Scott R BurtDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84604, USA.
Young Wan HamDepartment of Chemistry, Utah Valley University, 800 W University Pkwy, Orem, UT 84058, USA.
Yu Yeon JungDepartment of Dental Hygiene, Gwangyang Health Sciences University, Gwnagyang, Jeonnam 57764, Korea.
Jin Tae HongCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk 28160, Korea.
Chungbuk National University · KRBrigham Young University · USUtah Valley University · USGwangyang Health College · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a severely debilitating chronic autoimmune disease that leads to long-term joint damage. Signal transducer and activator of transcription 3 (STAT3)-targeted small molecules have shown promise as therapeutic drugs for treating RA. We previously identified (E)-2,4-bis(p-hydroxyphenyl)-2-butenal (BHPB), a tyrosine-fructose Maillard reaction product, as a small molecule with potent anti-inflammatory and anti-arthritic properties, mediated through the inhibition of STAT3 activation. The aim of this study was to develop a novel BHPH derivative with improved anti-arthritic properties and drug-likeness. We designed and synthesised (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol (MMPP), a novel synthetic BHPB analogue, and investigated its anti-inflammatory and anti-arthritic activities in experimentally-induced RA. We showed that MMPP strongly inhibited pro-inflammatory responses by inhibiting in vitro STAT3 activation and its downstream signalling in murine macrophages and human synoviocytes from patients with RA. Furthermore, we demonstrated that MMPP exhibited potent anti-arthritic activity in a collagen antibody-induced arthritis (CAIA) mouse model in vivo. Collectively, our results suggest that MMPP has great potential for use in the treatment of RA.

Indexed as

AgedAged, 80 and overAnimalsArthritis, ExperimentalArthritis, RheumatoidFemaleGene Expression RegulationHumansMaleMiceMiddle AgedPhenolsRAW 264.7 CellsSignal TransductionSTAT3 Transcription FactorSynoviocytesPhenolsSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID27845373
PMCPMC5109275
OpenAlexW2549899251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.